Date: September 22, 2026
Board Meeting Outcomes
- The Executive Committee of the Board of Directors approved the conversion of pre-existing inter-company loans into equity shares of wholly owned subsidiary Krystal Ingredients Private Limited.
- The meeting was held on September 22, 2026, commencing at 5:00 PM and concluding at 5:15 PM.
- The transaction does not involve any fresh infusion of capital by the Company.
Disinvestment / Strategic Actions
- Target Entity: Krystal Ingredients Private Limited (\"Krystal\")
- Transaction Type: Conversion of inter-company loans into equity shares
- Issue Price: ₹47,710 per share (comprising face value of ₹10 and premium of ₹47,700)
- Ownership Impact: No change in percentage of equity shareholding; Krystal will continue to remain a 100% wholly owned subsidiary
- Strategic Rationale: To strengthen Krystal's capital base and provide greater financial flexibility to support its business operations and future growth plans
- Completion Timeline: Within one month from receipt of requisite approvals
Subsidiary Details
- Incorporation Date: April 22, 2021
- Business: Manufacturing and exporting of Essential Oils, Aroma Chemicals and Specialty Chemicals and other related products
- Country Presence: India
Financial Performance of Krystal Ingredients
- FY 2025-26 Turnover: ₹3,23,296.64 (in Thousands) [₹32.33 crore]
- FY 2025-26 Net Worth: ₹5,98,643.63 (in Thousands) [₹59.86 crore]
- FY 2024-25 Turnover: ₹29,027.46 (in Thousands) [₹2.90 crore]
- FY 2023-24 Turnover: ₹1,111.35 (in Thousands) [₹0.11 crore]
Regulatory and Governance Aspects
- Related Party Status: Krystal is a wholly owned subsidiary and related party of Gem Aromatics Limited
- Promoter Interest: Promoters of Gem Aromatics Limited are Directors on the Board of Krystal Ingredients Private Limited
- Regulatory Exemption: Transaction is exempt from provisions applicable to Related Party Transaction under Listing Regulations as it is between holding company and its wholly owned subsidiary
- Arm's Length Basis: The transaction is conducted at arm's length
- Governmental Approvals: No regulatory approvals are required for the acquisition